Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate equivalent efficacy between two different
formulations of formoterol (pMDI using HFA-134 propellant and dry powder) on lung function in
adult patients with partially reversible COPD.
Phase:
Phase 2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Collaborators:
Cardarelli Hospital Carlo Mereu "Struttura complessa di Pneumologia", S. Corona Hospital, Pietra Ligure (Savona), Italy Fondazione Don Carlo Gnocchi Onlus Giovanni Barisione "Unità Operativa di Medicina Preventiva e del Lavoro, Laboratorio di Fisiopatologia Respiratoria", S. Martino Hospital, Genoa, Italy Roberto Dal Negro "Unità Operativa di Pneumologia", Hospital of Bussolengo (Verona), Italy Universita degli Studi di Genova University of Modena and Reggio Emilia University of Pisa Vito Brusasco "Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa, Italy (Co-ordinating centre)